In a recent public statement, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that U.S. Food & Drug Administration’s PCNS (Peripheral and Central Nervous System) had rescheduled the panel meeting to review eteplirsen. As per the reports, now the review meeting will take place on April 25, 2016 in place of previously scheduled January 22, 2016.

Eteplirsen is the lead pipeline candidate that Sarepta has been working on for months.

Insights of Matter

It’s not the lack of preparations of Sarepta that prompted FDA to postpone the review, but inclement weather conditions in the city. As soon as the news was announced, Sarepta’s shares gained more than 5.7% in intraday trading.

Sarepta is trying hard to get eteplirsen FDA approved as soon as possible, so that it can start the commercial deployment of the product for the treatment of those patients who are suffering from Duchenne muscular dystrophy.

FDA had first raised concerns against eteplirsen right before the January meeting of PCNS review panel. The doubts were unveiled in the briefing documents issued by the authority. In addition to this, a significant amendment submitted by Sarepta played a vital role in FDA’s approach towards reviewing this drug. So far, FDA has granted orphan drug and Fast Track status to eteplirsen.

DMD is one of the most dangerous health issues that affect one in every 3500-5000 newborn boys across the globe. As per the reports published by the company, eteplirsen can treat 13% of total patients affected by DMD. How investors react to this news will primarily depend on the outcome of the upcoming review meeting.

The senior management team of Sarepta hopes that things will fall in line and eteplirsen will get green signal from PCNS review panel in the upcoming meeting. It will keep all the investors informed about the outcome of this meeting via different communication channels.

Previous articleOpko Health Inc. (NYSE:OPK) Appoints New President of Bio-Reference Labs
Next articlebluebird bio Inc (NASDAQ:BLUE) Announces Changes In Senior Management And Board of Directors
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.